MarketPulse

type 2 inflammation

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron Win FDA Nod for Dupixent in Young Children With Chronic Urticaria

FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins FDA Nod for Young Children With Chronic Urticaria, Expanding Market Reach

FDA approves Dupixent for children ages 2-11 with uncontrolled chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi, Regeneron Win EU Nod for Dupixent in Young Children with Chronic Urticaria

Dupixent gains European approval for treating moderate-to-severe chronic spontaneous urticaria in children ages 2-11, expanding the drug's pediatric portfolio.
SNYREGNchronic spontaneous urticariaDupixent
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron's Dupixent Wins Japan Approval for Rare Skin Disorder

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.
SNYREGNmonoclonal antibodyclinical trial
BenzingaBenzinga··Vandana Singh

FDA Expands Dupixent Approval to Allergic Fungal Rhinosinusitis

FDA approves Dupixent for allergic fungal rhinosinusitis in patients six and older, marking the drug's ninth indication for treating type 2 inflammatory conditions.
SNYREGNFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

European Regulators Approve GSK's Biannual Asthma Drug Targeting Type 2 Inflammation

European regulators approve GSK's Exdensur, a biannual asthma injection targeting type 2 inflammation. The drug also treats chronic rhinosinusitis with nasal polyps, showing significant exacerbation reductions in trials.
GSKPhase 3 trialssevere asthma